Navigation Links
Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
Date:10/2/2008

Study to support Urgent PC clinical success and expanded reimbursement

coverage

MINNEAPOLIS, Oct. 2 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today the enrollment of the first patients in a new randomized, controlled multicenter clinical study of its FDA cleared Urgent PC neuromodulation system for the treatment of overactive bladder (OAB) symptoms of urinary urgency, urge incontinence and frequency of urinary voids.

The study is designed to directly compare the effectiveness of Urgent PC treatment to non-active treatment. Uroplasty is undertaking this study primarily to support third-party reimbursement coverage. The study will evaluate reductions in urinary urgency, urge incontinence and frequency of urinary voids, as well as patient quality of life measures. This study, expected to be completed by early fall of 2009, is to take place at approximately 20 urology and urogynecology centers across the United States, with total enrollment of 214 patients. As previously discussed, Uroplasty has reallocated expenditures this fiscal year to expedite these efforts, and expects to spend between $1.0 million and $1.4 million this fiscal year on the study.

More than 33 million Americans suffer from OAB symptoms, dramatically impacting the quality of their lives. The Urgent PC system is a minimally invasive, office-based, nonsurgical, percutaneous tibial nerve stimulation (PTNS) device that treats these symptoms. The Company believes physicians, patients and many third party payers are embracing the Urgent PC therapy because this low cost, non-surgical, non-drug treatment alternative is clinically effective.

Kenneth M. Peters, M.D., the Principal Investigator leading this study, is internationally known for his work on neuromodulation, interstitial cystitis, and painful bladder syndrome. Dr. Peters is the Chairman of the Department of Urology and Director of Clinical Research -- Depart
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
3. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
4. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
8. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. First European Patients Treated With the Percutaneous MitraClip(R) System
11. Trius Doses First Patient in Antibacterial Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...l Results from prior U.S., U.K. and China Trials ,...apies, Inc. (VTI), a development stage company tar...llment has begun for a randomized, controlled, mul...the Extracorporeal Liver Assist Device (ELAD) as a...ALF) under three protocols. The study is open for ...
(Date:1/6/2009)...Newswire/ -- Cequent Pharmaceuticals, a pioneer in...-based treatments to prevent and treat human disea...ted a successful toxicology study of its candidate...ic targeting the primary oncogene (beta-catenin, C...P is an inherited gastrointestinal disease that ca...
(Date:1/5/2009)... Women undergoing in vitro,fertil...elp support early,pregnancy, but the intramuscula...n be painful for patients. Formulations of proges...bcutaneous injection or vaginal suppository may of.... , With patient well-being a constant focu...
(Date:12/27/2008)...27 According to the latest,scienc...ume modest doses of,resveratrol plus an array of ...to 5 glasses of aged, red wine, rather than resver....com/cgi-bin/prnh/20080603/LATU039 ) , The...ne fails to prolong,the life of laboratory mice. ...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Live Christmas Trees Can Trigger Mold Allergies 6510 1Live Christmas Trees Can Trigger Mold Allergies 6510 2Live Christmas Trees Can Trigger Mold Allergies 6510 3Geisinger rheumatologists redesign osteoporosis rheumatoid arthritis care 6507 1Geisinger rheumatologists redesign osteoporosis rheumatoid arthritis care 6507 2Update 3A Oscar Nominated Actress Signs on as Neutrogena 28R 29 Brand Ambassador 6505 1Update 3A Oscar Nominated Actress Signs on as Neutrogena 28R 29 Brand Ambassador 6505 2Continental Airlines Sponsors Golfers Against Cancer Tournament 6502 1
...-(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScienc...armaceutical,company, discussed results from two p...otherapy induced angiogenesis and,rationale for co...,Suspension (paclitaxel protein-bound particles fo...F inhibitor drugs like,bevacizumab (Avastin(R)) at...
...-(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScienc...armaceutical,company, announced results from two p... (secreted protein acidic and rich in,cysteine) ex...in-bound (nab(TM)) tumor-targeting technology at t...AACR) Annual Meeting held,April 14-18, 2007 in Los...
Other Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:1/8/2009)...ole introduces Senator Daschle at his confirmation...man Services , , , WASHINGTON, Jan. 8 /PRNews... founding board member Senator Tom Daschle, nomine...etary, was introduced by fellow BPC founder and fr...today. The hearing was convened by the Senate Heal...
(Date:1/8/2009)...at St. Jude Children,s Research Hospital have demo...pneumonia following influenza. They found that the...ill bacteria by inhibiting their protein synthesis...eatment with the "beta-lactam" antibiotic ampicill... , The finding is important because pneumonia, r...
(Date:1/8/2009)...RANCISCO, Jan. 8 Medivat...David Hung, M.D., president and chief,executive o...n Healthcare,Conference on Wednesday, January 14,...ncis Hotel in San Francisco. , Dr. Hung wil...al,development programs for Dimebon for Alzheimer...
(Date:1/8/2009)...a., Jan. 8 Cephalon, In...aldino, Jr., Ph.D., Chairman and CEO will present...eld on January 13, 2009 in San Francisco, CA at ap... Time). The presentation will be webcast live on t...site. , , The webcast will be archived for one...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...phy from Newfoundland has been charged of intentio...positive woman who has pleaded guilty against a se...ressed that she did not sexually assault any soldi...ve asked its official to undergo medical tests if ...
...onclave will be opened by India’s Health Minister ...ave will review the progress made towards achievin...h. The conclave is expected to make recommendation...a for achieving the goals, according to the Confed...
...g revelation, a recent survey by the Confidential ...dicates that there are at least 50 cases // a year...pts. The systematic investigation by CEMACH, whic...of Britain's six royal colleges of medicine, comes...
... a latest survey, there is a steady decline in the... Britain // . The findings were presented at the ...th of this month by researchers from Cancer Resear...n of Cancer Registries. The survey revealed, that...
Other Medicine News:
...hip Camera System offers 800+ lines of resolution ...ic gain control, and white balance features in a u...stem for Microscopic Application, Domestic (MS 100...CCU) with power cord and video cables , (MS 1000-0...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides a combination of concentrated cold / hot and compression for the neck
Provides a combination of concentrated cold / hot and compression for the ankle
Medicine Products: